Chronic Inflammatory Condition of the Male Genital Tract (URIS)

Study of the Prevalence of a Chronic Inflammatory Condition of the Male Genital Tract at a Distance and Urethritis Following.

Men following after proven and treated urethritis, looking for signs of chronic genital inflammatory syndrome with oxidative stress.

This group of patients will be compared to a control group with no urethritis and no history of urogenital infection. Monocentric, prospective trial.

Duration of study : one year

Study Overview

• Status: Completed
• Conditions: Urethritis
• Intervention / Treatment: Other: Sperm sample

Detailed Description

The presence of leucospermia in an chronic inflammatory genital tract syndrome leads to an oxidative stress and alterations in sperm parameters. Inflammation also affect the glands of the genital tract. This can eventually leads to male infertility, long after the initial infection. But 10% of men who seek treatment for infertility have such a leucospermia, while it is a potentially treatable cause.

Main aim of this study: Search of development of an inflammatory genital tract syndrome in patients with urethritis proven and treated at 6 months after the end of treatment.This group of patients will be compared to a control group with no urethritis and no history of urogenital infection. Monocentric, prospective trial.

Primary endpoint: Seminal elastase value to 6 months after the end of treatment. (500ng/ml or greater)

Secondary objective:

• Search for a genital inflammation in patients with urethritis proven and treated at 12 months after the end of treatment
• Search for oxidative stress in patients with urethritis proven and treated at 6 and 12 months after the end of treatment
• Study of the frequency of relapses infectious and / or passages at the stage of chronic infection after acute urethritis
• Assessment of the parallel evolution of the quality of sperm in the two groups

Progress of research. Time frame Search :

• Duration of inclusions: 12 months
• Duration of patient follow-up: 12 months for control group, 14 months at most for patients taking into account the duration of treatment for urethritis which is 4 to 6 weeks
• Total duration of the study: 26 months

Patients & Methods: French monocentric, prospective trial. 300 subjects are planned to be included for 150 subjects in each group

• Study Type: Interventional
• Enrollment (Actual): 113
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Paris, France, 75014
    • Hospital Cochin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion criteria common to both groups:

• Subjects aged 18 and over
• Voluntary and signed informed consent

Inclusion criteria specific to the group "patient":

• Patients with clinical signs of urethritis / or
• Patients treated for urethritis following the usual protocols in the month before inclusionand / or
• Patients with positive chlamydial research, or Mycoplasma genitallium or Garderella vaginalis or gonorrhea in the sperm or first urinary stream;

Inclusion criteria specific to the group "control":

- Patients with no urethritis or no history of urogenital infection

Exclusion criteria common to both groups:

• Subjects not wishing to participate in the study
• Subjects that have not signed the informed consent
• Those not affiliated to the social security system (or entitled beneficiary)
• Immunodepressed or have an infection associated with HIV, HBV or HCV
• Chronic systemic disease

Exclusion criteria specific to the group "patient":

- Patients with no signs of urethritis

Exclusion criteria specific to the group "control":

- Subjects with signs of urethritis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Patient Group; Patient with urethritis	Other: Sperm sample; Sperm sample
Other: Control group; Subjects with no urethritis and no history urogenital infection	Other: Sperm sample; Sperm sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Seminal elastase value	The dosage of elastase will be do 6 months after the end of treatment.	6 months after the end of treatment.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Seminal elastase value	The dosage of elastase will be do 12 months after the end of treatment.	12 months after the end of treatment.
Presence of markers of oxidative stress	Presence of markers objectifying the existence of oxidative stress resulting in cellular alterations: Determination of 8-hydroxydeoxyguanosine (8-OHdG) and AOPP (Advanced Oxidation Protein Products)	6 to 12 months after the end of treatment
Functional impairment of the glands of the reproductive tract	Presence of biochemical evidence indicating a functional impairment of the glands of the reproductive tract (markers of prostate, seminal vesicles, and epididymis to the seminal biochemistry)	6 to 12 months after the end of treatment
Signs reflecting the sperm function	Presence of signs reflecting the sperm function (vitality, mobility, analysis of motion parameters by Computer Assisted Semen Analyzer(CASA))	6 to 12 months after the end of treatment

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Jean-Philippe WOLF, MD, PhD, Cochin Hospital; Principal Investigator: Khaled POCATE, MD, Cochin Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 10, 2012
• Primary Completion (Actual): February 29, 2016
• Study Completion (Actual): February 29, 2016

Study Registration Dates

• First Submitted: November 19, 2012
• First Submitted That Met QC Criteria: November 19, 2012
• First Posted (Estimate): November 22, 2012

Study Record Updates

• Last Update Posted (Actual): March 19, 2018
• Last Update Submitted That Met QC Criteria: March 16, 2018
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Keywords: Urethritis; Prevalence of a chronic inflammatory male genital tract
• Additional Relevant MeSH Terms: Urologic Diseases; Urethral Diseases; Urethritis
• Other Study ID Numbers: P 111004